FRANKFURT, Feb 5 (Reuters) - Bayer said on Thursday its experimental blood thinner cut the risk of stroke recurrence by 26% ...

Among adults with acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA) with planned ...

Overall, women who stuck most closely to an eating pattern resembling the Mediterranean diet had an 18% lower risk of any ...

The rationale behind the treatment is that because genetic FXI deficiency has been linked with reduced risk of ischemic ...

Stroke recovery improves when care addresses social needs like reducing loneliness and depression and strengthening support.

Getting to the bottom of the cause in this 29-year-old woman illustrates the diagnostic co ...

An investigational anti-clotting medication, asundexian, has demonstrated a reduction in the risk of a second ischemic ...

Expanded eligibility for advanced ischemic stroke therapies and the first detailed recommendations pediatric stroke care are ...

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and Johnson & Johnson’s rival factor XIa inhibitor in a blockbuster indication.

CHOICE-2 supports intra-arterial alteplase after successful reperfusion ...

Manual review of electronic health records (EHRs) to screen for contraindications to thrombolysis during stroke evaluation is ...

More than 5,000 medical professionals are in New Orleans for the American Stroke Association International Stroke Conference ...